Clinical Trial Results:
Modulation of the FOLFIRI-based standard 1st-line therapy with cetuximab, controlled by monitoring the RAS mutation load by liquid biopsy in RAS-mutated mCRC patients
|
Summary
|
|
EudraCT number |
2019-003714-14 |
Trial protocol |
DE AT |
Global completion date |
|
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
|
Results information
|
|
Results version number |
v3(current) |
This version publication date |
19 Nov 2025
|
First version publication date |
25 May 2025
|
Other versions |
v1 (removed from public view) , v2 |
Version creation reason |
|
Summary report(s) |
MoLiMoR_TheraOP_ CSR_v2.0_2025_10_21_Synopsis_corrected_clean_redacted_for-EudraCT MoLiMoR_TheraOP_ CSR_v2.0_2025_10_21_corrected_clean_signed_redacted |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.